Biopharmaceutical giant AbbVie will invest $380 million to build two new manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.
The investment is part of AbbVie’s broader effort to scale up domestic manufacturing, and part of its $100 billion commitment to U.S. research and development and capital investments, including manufacturing, over the next decade. The new state-of-the-art facilities will integrate advanced manufacturing technologies.
Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029. To support these new facilities, AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.
“By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients,” said Robert A. Michael, chairman and chief executive officer, AbbVie.
Don’t miss Carter Andrus, Chief Operating Officer of Prologis, as the keynote interview at Connect Industrial Midwest— taking place Tuesday afternoon, March 10, 2026, at Joe’s Live in Rosemont, IL.
The post AbbVie Advances US Expansion With $380M for Two Chicago Plant appeared first on Connect CRE.